Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $18.3 million.

  • Ocular Therapeutix's Gains from Investment Securities fell 773.69% to $18.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $18.7 million, marking a year-over-year decrease of 621.33%. This contributed to the annual value of $19.1 million for FY2025, which is 377.05% down from last year.
  • As of Q4 2025, Ocular Therapeutix's Gains from Investment Securities stood at $18.3 million, which was down 773.69% from $1.5 million recorded in Q3 2025.
  • Ocular Therapeutix's 5-year Gains from Investment Securities high stood at $19.9 million for Q4 2024, and its period low was $1000.0 during Q3 2022.
  • For the 5-year period, Ocular Therapeutix's Gains from Investment Securities averaged around $4.5 million, with its median value being $1.7 million (2024).
  • Per our database at Business Quant, Ocular Therapeutix's Gains from Investment Securities plummeted by 9996.19% in 2023 and then soared by 58167460.0% in 2024.
  • Ocular Therapeutix's Gains from Investment Securities (Quarter) stood at $6.8 million in 2021, then crashed by 97.24% to $187000.0 in 2022, then skyrocketed by 46.52% to $274000.0 in 2023, then surged by 7158.28% to $19.9 million in 2024, then dropped by 7.74% to $18.3 million in 2025.
  • Its Gains from Investment Securities was $18.3 million in Q4 2025, compared to $1.5 million in Q3 2025 and $29000.0 in Q2 2025.